Search Results
Sep 04, 2025, 17:46 ET Gaucher's Disease Market to Witness Significant Upswing During the Forecast Period (2025-2034) Amid New Treatment Options | DelveInsight
with a regulatory filing planned for 2026 based on these results. Eli Lilly's PR001 is an AAV9-based gene replacement therapy delivering a functional copy of the GBA1 gene to the brain. A Phase I/II clinical trial (PROCEED) is underway evaluating PR001 in patients with peripheral manifestations
More news about: DelveInsight Business Research LLP
Sep 04, 2025, 11:35 ET RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033, Report by DataM Intelligence
The breakthrough approval of Onpattro (patisiran) in 2018 marked the first siRNA drug to reach patients, validating gene silencing as a viable medical strategy. This success was quickly followed by other Alnylam products like Givlaari (givosiran) for acute hepatic porphyria,
More news about: DataM Intelligence 4 Market Research LLP
Sep 04, 2025, 11:00 ET NRGene Achieves Full Clubroot Resistance in Canola and Moves Toward Commercialization in Canada
Non-GMO Precision: Achieved through genomics and AI-driven tools to identify natural clubroot resistance genes, enable efficient gene pyramiding, and apply targeted introgression using advanced molecular breeding technologies, supporting rapid regulatory acceptance and global deployment.Proven
More news about: NRGene
Sep 04, 2025, 11:00 ET NRGene Achieves Full Clubroot Resistance in Canola and Moves Toward Commercialization in Canada
Non-GMO Precision: Achieved through genomics and AI-driven tools to identify natural clubroot resistance genes, enable efficient gene pyramiding, and apply targeted introgression using advanced molecular breeding technologies, supporting rapid regulatory acceptance and global deployment.Proven
More news about: NRGene
Sep 04, 2025, 09:32 ET Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
of drug-related complications1. The Quest PGx offering includes 17 genes and 4 HLA alleles, encompassing genes with recognized evidence of gene-drug associations and defined medical utility. These genes possess clinically actionable pharmacogenetic associations informed by expert groups like
More news about: Quest Diagnostics
Sep 04, 2025, 09:03 ET EQUASHIELD® Launches CellSHIELD®: A New Era in Cell and Gene Therapy Manufacturing
the scalability required to meet the growing demand for cell and gene therapies." Showcasing at Cell and Gene Meeting on the Mesa EQUASHIELD® will be showcasing CellSHIELD® at the Cell and Gene Meeting on the Mesa, taking place October
More news about: Equashield LLC
Sep 04, 2025, 09:00 ET What's driving medical benefit spend? Prime Therapeutics trend report shares new clues
Medicaid lines of business. This in-depth analysis identifies opportunities for site-of-care optimization and evaluating the impact of biosimilars, gene therapies and new approvals. And for the first time, it includes integrated medical and pharmacy claims data for certain therapeutic categories for
More news about: Prime Therapeutics LLC
Sep 04, 2025, 09:00 ET OncoHost to Present New Research on Small Cell Lung Cancer Subtypes at WCLC 2025
stratification involves molecular subtyping based on transcription factor expression in tumor samples. These subtypes exhibit unique biological features and gene expression profiles that give rise to subtype-specific therapeutic vulnerabilities. Emerging evidence therefore suggests that integrating SCLC subtyping
More news about: OncoHost
Sep 04, 2025, 09:00 ET Everyday Dose Finds More Than 1 in 3 Americans Get Jitters From Coffee - Hurting Focus, Raising Anxiety, and Disrupting Their Day
NIH-backed studies, showing that certain variations in the CYP1A2 gene (that about 50% of people were found to have) slow caffeine metabolism, causing its stimulating effects to last longer. For millions, that means even
More news about: Everyday Dose
Sep 04, 2025, 08:30 ET Advancing Gene Therapy Development with Monoclonal HEK293 Cell Isolation for Regulatory Compliance, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn why demonstrating clonality is critical to gene therapy manufacturing and how image-based documentation supports regulatory compliance. Attendees will learn how static culture conditions impact single-cell cloning in HEK293 lines adapted for suspension. The featured
More news about: Xtalks
Sep 04, 2025, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for September 2025
InsightsSeptember 25 - Advancing Gene Therapy Development with Monoclonal HEK293 Cell Isolation for Regulatory Compliance (Broadcast 1)September 25 - Advancing Gene Therapy Development with Monoclonal HEK293 Cell Isolation for Regulatory
More news about: Xtalks
Sep 04, 2025, 07:00 ET AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS)
"This is the first Phase 2 study to assess a SOD1-targeted therapeutic in both sporadic ALS and in ALS patients with mutations in the SOD1 gene. The study allowed us to rigorously assess patient safety, pharmacokinetics, and early signals of biological activity," said Peter
More news about: AL-S Pharma AG
Sep 03, 2025, 16:09 ET PLPC-DB™: Non-Cellular Oncology Immunotherapy with STIP-NAM Traceability, Entering a Global Acquisition Window.
non-cellular oncology immunotherapy platform designed to overcome the barriers of cost, scalability, and infrastructure in cancer innovation. Unlike cell- or gene-based therapies, PLPC-DB is a lyophilized phospholipoproteic complex with validated stability for more than 18 months at room temperature, eliminating
More news about: OGRD Alliance
Sep 03, 2025, 14:19 ET Cayman Chemical and Curapath Partner to Provide Wider Access to PEG-Free Shielding Lipids for Lipid Nanoparticles
nanoparticle (LNP) development have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-viral drug delivery, gene therapy, mRNA vaccines, and biologic therapies. Cayman Chemical, a global supplier of high-quality lipids for LNPs, has partnered with Curapath,
More news about: Cayman Chemical
Sep 03, 2025, 10:51 ET FDA grants HERNEXEOS® Breakthrough Therapy Designation for first line use in HER2 (ERBB2)-mutant advanced NSCLC
has spread to other parts of your body (metastatic), andhas a certain mutation in the human epidermal growth factor receptor 2 (HER2) gene, andwho have previously received treatment by mouth or injection (systemic therapy).Your healthcare provider will perform
More news about: Boehringer Ingelheim
Sep 03, 2025, 10:30 ET GMP Cell Therapy Consumables Market to Reach USD 114.4 Million by 2035, with CAGR 28.9% Driven by Advanced Cell Therapy and Biopharmaceutical Innovation | Vantage Market Research
NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Rising adoption of cell and gene therapies, along with increasing investments in biopharmaceutical R&D, is accelerating demand for GMP-grade consumables essential for the manufacturing,
More news about: Vantage Market Research
Sep 03, 2025, 10:11 ET MyOme Expands Proactive Health Portfolio with Launch of Type 2 Diabetes Integrated Polygenic Risk Score (iPRS)™
long-term health." The T2D iPRS joins MyOme's growing portfolio of Proactive Health offerings, which include: Single-Gene Screen Report: Identifies disease-causing variants in genes linked to a range of conditions including cancers, heart disease, and metabolic and
More news about: MyOme, Inc
Sep 03, 2025, 09:15 ET Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
transform biologic discovery." Proteomics offers a view into proteins and their functions in biologic processes. Understanding their roles in gene expression and how proteins change throughout disease states is critical to biomarker discovery and precision therapy development. Illumina Protein
More news about: Illumina, Inc.
Sep 03, 2025, 09:15 ET Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
transform biologic discovery." Proteomics offers a view into proteins and their functions in biologic processes. Understanding their roles in gene expression and how proteins change throughout disease states is critical to biomarker discovery and precision therapy development. Illumina Protein
More news about: Illumina, Inc.
Sep 03, 2025, 09:04 ET Orsini and Paynela Partner to Expand Affordability and Copay/Coinsurance Support Programs for Rare Disease Patients
paynela.com. About Orsini Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Sep 03, 2025, 08:00 ET Andelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten Disease
for organizations advancing life-changing gene therapies. About Andelyn Biosciences, Inc. Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production of viral vectors for gene therapy. With more than 20 years of experience,
More news about: Andelyn Biosciences
Sep 03, 2025, 07:40 ET Molecular Designs Launches Urogenital Microbiota Panel to Detect Pathogens and Antibiotic Resistance
Greer Massey, Chief Scientific Officer at Molecular Designs. "By combining urogenital target detection with resistance gene profiling in a single panel, this product gives researchers the insight they need to track emerging threats and make more informed decisions, faster."
More news about: Molecular Designs
Sep 03, 2025, 07:37 ET 10 Pet Breeds That Tend to Hide Chronic Health Problems in Plain Sight
healthier, happier lives." Cat Breeds to Watch Scottish Fold – osteoarthritis + kidney diseaseThe ear-fold gene also affects cartilage in legs and tail, so painful arthritis can start young; kidney cysts or inherited changes have been reported in the breed.
More news about: Thrive Pet Healthcare
Sep 03, 2025, 07:30 ET Allucent Expands Leadership Team to Advance Innovation in Drug Development for Biopharma Customers
recognized for scaling high-performing teams and forging strong client partnerships across therapeutic areas, including oncology, rare diseases, cell and gene therapy, and neuroscience. Nate Thompson – chief information officer As CIO, Nate
More news about: Allucent
Sep 03, 2025, 07:15 ET SpliSense Reports Positive Results from Phase 2 Study of SPL84 in Cystic Fibrosis
oligonucleotide (ASO), for the treatment of people with cystic fibrosis (CF) carrying the 3849+10 kilobase (Kb) C->T splicing mutation in the CFTR gene. The SPL84-002 study is ongoing in a number of centers in the US and Europe. The data, based on the complete
More news about: SpliSense